FDA Details Investigation Into 2026 Salmonella Outbreak Linked to Moringa Powder
The U.S. Food and Drug Administration (FDA) has released an Executive Incident Summary (EIS) detailing its investigation into a 2026 multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules, including traceback findings, inspection observations, and product sampling results.
The outbreak investigation was announced in May 2026 and declared over in July with 34 sick across 14 states, resulting in 11 hospitalizations. MOGO Moringa LLC recalled two lots of MOGO-brand moringa capsules during the investigation. Based on the epidemiological and traceback evidence, FDA confirmed moringa leaf powder as the outbreak vehicle and identified moringa powder from a single redacted supplier as the likely source for a majority of cases.
At the time the outbreak was declared over, FDA announced it had increased screening of imported moringa powder from India for Salmonella in the interest of public health.
The outbreak detailed in the present EIS was one of three salmonellosis outbreaks linked to moringa supplements in 2026, shining a light on the vulnerabilities of botanical ingredient supply chains.
As in previous EISs, FDA redacted the names of implicated suppliers and upstream firms.
FDA Traceback Investigated Moringa Supply Chain
According to the EIS, FDA’s Coordinated Outbreak Response and Evaluation (CORE) Network was notified by the U.S. Centers for Disease Control and Prevention (CDC) on May 13, 2026 about a cluster of S. Typhimurium illnesses spanning 12 states. A strong epidemiological signal identified moringa powder capsules, particularly MOGO-brand moringa capsules, as the exposure of interest.
FDA conducted traceback for MOGO-brand moringa capsules consumed by five ill people in Florida, Oregon, Tennessee, and Washington, as well as TNVitamins Ultrapotent Moringa Powder Capsules consumed by one ill person in North Carolina. Where purchasing information was available, the products were reported to have been purchased through Amazon.
Looking for quick answers on food safety topics?
Try Ask FSM, our new smart AI search tool.
Ask FSM →
MOGO Moringa LLC produced the MOGO-brand capsules and sourced imported raw moringa powder from a supplier in India, which obtained moringa from two small farms in India. FDA said traceback convergence was not identified, but a majority of cases were traced back to a single redacted supplier.
FDA Inspections Identified Food Safety Deficiencies, Form 483s Issued
On May 22, FDA CORE issued a dietary supplement inspection, including retain sampling, to a redacted firm. FDA issued a Form 483 citing issues with product specifications, contamination limits, and adherence to procedures. All samples collected during the inspection tested negative.
On June 5, FDA’s Division of Foreign Food Inspections and Global Operations/India Office issued a limited-scope Preventive Controls inspection for a redacted firm. FDA issued another Form 483 citing a lack of written records and procedures, cleaning and sanitation issues, inadequate hazard controls, personnel practices, and problems with facility design and maintenance.
Opened Product Samples Test Positive
Meanwhile, state partners in Washington, Tennessee, and Florida collected five product samples from ill people’s homes, of which opened containers tested positive for the outbreak strain. Another sample tested positive for an additional serotype, Salmonella IV 48:g,z51:-.
